**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准:治疗复发或难治性多发性骨髓瘤

2020-08-06 MedSci原创 MedSci原创

FDA的批准使得Blenrep成为世界上第一个靶向BCMA的抗体-药物偶联物。

GlaxoSmithKline宣布FDA加快批准Blenrep(belantamab mafodotin-blmf),用于治疗已接受过至少四种先前疗法(包括抗CD38单抗,蛋白酶体抑制剂和免疫调节剂)的复发或难治性多发性骨髓瘤成人患者。

See the source image

图片来源:https://www.adcreview.com/news/belantamab-mafodotin-receives-priority-review-for-relapsed-or-refractory-multiple-myeloma/

Blenrep是靶向B细胞成熟抗原(B Cell Maturation Antigen,BCMA)的抗体-药物偶联物(ADC),该药物是将抗BCMA单抗与细胞毒药物monomethyl auristatin-F通过连接子相连。抗BCMA单抗靶向结合多发性骨髓瘤细胞表面的BCMA,之后被肿瘤细胞细胞内化释放出非渗透性的细胞毒药物发挥抗肿瘤作用。

GSK指出FDA的批准使得Blenrep成为世界上第一个靶向BCMA的抗体-药物偶联物。

FDA咨询小组以 12 票对0 票的投票批准了该药物。但是在关键的DREAMM-2试验中观察到Blenrep的眼毒性。角膜病变是该研究中最常见的不良事件,总发生率为71%,而44%的患者在2.5 mg/kg剂量下经历了至少一次严重的角膜病变。

最近,欧洲药品管理局的人用药品委员会建议授予Blenrep有条件的上市批准,以治疗对免疫调节剂、蛋白酶体抑制剂和抗CD-38单抗治疗无效的复发和难治性多发性骨髓瘤患者。

原始出处:

https://www.firstwordpharma.com/node/1746883?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2021-04-08 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-08 yykkxiaodou
  7. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-08 freve
  8. [GetPortalCommentsPageByObjectIdResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99888, encryptionId=e92d9988838, topicName=靶向BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Fri Jun 18 01:54:30 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957640, encodeId=b6ef195e6404b, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jul 11 13:54:30 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890144, encodeId=2287189014481, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Apr 08 20:54:30 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Dec 17 08:54:30 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413833, encodeId=bba31413833c8, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528679, encodeId=9ed915286e936, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Aug 08 12:54:30 CST 2020, time=2020-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806665, encodeId=2e8080666535, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Thu Aug 06 22:12:04 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-06 14758c02m67暂无昵称

    0

相关资讯

Blood:应以微小残留病灶检测阴性作为高风险多发性骨髓瘤的治疗终点

与标准细胞遗传学异常(CA)风险的病例相比,携带高CA风险的多发性骨髓瘤(MM)患者尽管达到了相似的完全缓解(CR)率,但预后较差。

Blood:JAK-STAT通路调控骨髓瘤CD38表达,可作治疗靶点

骨髓瘤患者的骨髓基质细胞通过激活JAK-STAT3途径下调骨髓瘤细胞上的CD38表达。JAK抑制剂鲁索替尼上调骨髓瘤细胞上CD38的表达并增强达雷木单抗介导的细胞毒性。

Blood:一种新的高还原的多发性骨髓瘤小鼠模型

生发中心B细胞表达NrasQ61R和MYC可诱发高度恶性的MM;VQ MM模型为新药物提供了一个预临床实验平台。

蒽环类药物在不同恶性肿瘤中的应用价值

蒽环类药物在肿瘤内科治疗中广泛应用,是具有代表性的细胞毒类药物。过去几十年中,虽然靶向药物、免疫治疗药物等为肿瘤治疗带来了新的突破,但是蒽环类药物仍然在乳腺癌、肝癌等很多实体肿瘤和多发性骨髓瘤(MM)

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤:已提交BLA

idecabtagene vicleucel(ide-cel,bb2121)是一款研究性靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)T细胞免疫疗法,用于治疗复发难治性多发性骨髓瘤。

Lancet:卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤

卡非佐米、达雷木单抗联合地塞米松治疗可显著延长复发或难治性多发性骨髓瘤患者的无进展生存期